AbbVie could learn this week whether the European Medicines Agency will recommend EU approval to extend the indication of Skyrizi (risankizumab) to include use of the blockbuster plaque psoriasis drug as a treatment for active psoriatic arthritis in adults.
Also, the EMA is set to decide whether Eli Lilly’s immunosuppressant Olumiant (baricitinib) should be recommended for use as...








